Biosimilars are a type of biological pharmaceutical product that is highly similar to an existing biologic drug, known as a reference product. Biosimilars are designed to have comparable efficacy, safety, and quality as the reference product, but at a lower cost due to reduced development and manufacturing expenses. Biosimilars are an important area of research and development in the pharmaceutical industry as they have the potential to increase access to effective treatments, promote competition, and reduce healthcare costs. However, the development and approval of biosimilars is a complex and highly regulated process that requires extensive comparative analytical and clinical studies to demonstrate similarity to the reference product.